Therapy Areas: Diabetes
Oramed announces US patent for oral Exenatide
5 April 2019 -

Oral drug delivery systems developer Oramed Pharmaceuticals Inc (NASDAQ:ORMP) (TASE:ORMP) reported on Thursday the receipt of a US patent for the technology "Methods and Compositions for Oral Administration of Exenatide".

The Methods and Compositions for Oral Administration of Exenatide patent was granted by the US Patent and Trademark Office.

According to CEO Nadav Kidron, this is another important patent in the company's patent portfolio that protects a key aspect of its breakthrough technology with regard to oral Exenatide. This patent allowance comes as it is completing its phase I study with its ORMD-0901 oral Exenatide capsule under an IND in the US.

Established in 2006, the company's Protein Oral Delivery (POD) technology is based on over 30 years of research by scientists at Jerusalem's Hadassah Medical Center. It is seeking to revolutionise the treatment of diabetes through its proprietary flagship product, an orally ingestible insulin capsule (ORMD-0801).

Login
Username:

Password: